Home › Compare › PLNTQ vs ABBV
PLNTQ yields 2000000.00% · ABBV yields 3.06%● Live data
📍 PLNTQ pulled ahead of the other in Year 1
Combined, PLNTQ + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PLNTQ + ABBV for your $10,000?
Proliance International, Inc. designs, manufactures, and markets heat exchange products and temperature control parts for the automotive and light truck aftermarket, as well as heat exchange products. The company's heat exchange products include radiators, heater cores, heaters, radiator cores, and condensers; and temperature control parts comprise condensers, compressors, accumulators/driers, and evaporators. It also offers air conditioning parts and supplies, such as hose and tube assemblies, expansion valves, blowers, and fan clutches. In addition, the company provides charge air coolers, oil coolers, marine coolers, and other specialty heat exchangers for heavy-duty trucks, buses, specialty equipment, and industrial and marine applications, such as agricultural, construction and military vehicles, oil rigs, stationary power generation equipment, and inland sea-going vessels. Its customers include national retailers of aftermarket automotive products, warehouse distributors, radiator shops, hard parts jobbers, and other manufacturers. The company offers its products in the United States, Canada, Mexico, Europe, and Central America. Proliance International, Inc. was formerly known as Transpro, Inc. and changed its name to Proliance International, Inc. in July 2005. The company was founded in 1915 and is based in New Haven, Connecticut.
Full PLNTQ Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.